Exact Sciences Corporation Partners with Freenome for Exclusive Blood-Based Colorectal Cancer Screening Tests
Reuters
Aug 07, 2025
Exact Sciences Corporation Partners with Freenome for Exclusive Blood-Based Colorectal Cancer Screening Tests
Exact Sciences Corporation has entered into an exclusive licensing agreement with Freenome, a biotechnology company specializing in early cancer detection. Under this partnership, Exact Sciences will acquire exclusive rights in the United States to Freenome's blood-based colorectal cancer screening tests. This collaboration aims to enhance Exact Sciences' leadership in cancer screening by introducing blood-based options, alongside its existing Cologuard Plus test, to address the needs of over 50 million unscreened Americans. The agreement includes Exact Sciences' commitment to invest $20 million annually in joint R&D efforts over three years and a $50 million purchase of a senior convertible note from Freenome. Additionally, Exact Sciences will provide milestone payments contingent on FDA approvals and performance benchmarks, with potential payouts totaling up to $700 million. This partnership is expected to expedite the delivery of advanced cancer screening technologies to patients, leveraging Exact Sciences' extensive commercial network and expertise.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806361618) on August 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.